US20090258840A1 - Method and compositions for treating hematological malignancies - Google Patents

Method and compositions for treating hematological malignancies Download PDF

Info

Publication number
US20090258840A1
US20090258840A1 US12/298,987 US29898707A US2009258840A1 US 20090258840 A1 US20090258840 A1 US 20090258840A1 US 29898707 A US29898707 A US 29898707A US 2009258840 A1 US2009258840 A1 US 2009258840A1
Authority
US
United States
Prior art keywords
compound
tautomers
solvates
organic acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/298,987
Other languages
English (en)
Inventor
Lee S. Chong
William S. Lee
Adrian S. Ray
Hans Reiser
Daniel B. Tumas
William J. Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to US12/298,987 priority Critical patent/US20090258840A1/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JIN, HAOLUN, JABRI, SALMAN Y., CAI, ZHENHONG R., LANSDOWN, RACHEL A., METOBO, SAMUEL E., MISH, MICHAEL R., PASTOR, RICHARD M.
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TUMAS, DANIEL B., LEE, WILLIAM A., RAY, ADRIAN S, CHONG, LEE S., REISER, HANS, WATKINS, WILLIAM J.
Publication of US20090258840A1 publication Critical patent/US20090258840A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • cpr-PMEDAP N-6 cyclopropylPMEDAP
  • cpr-PMEDAP N-6 cyclopropylPMEDAP
  • WO 02/08241 discloses a method for screening methoxyphosphonate nucleotide analogue prodrugs that are useful for treating hematological malignancies with reduced toxicity.
  • lymphomas malignant masses of lymphoid cells, primarily but not exclusively in lymph nodes
  • leukemias neoplasm derived typically from lymphoid or myeloid cells and primarily affecting the bone marrow and peripheral blood.
  • the lymphomas can be sub-divided into Hodgkin's Disease and Non-Hodgkin's lymphoma (NHL).
  • NHL Hodgkin's Disease
  • NHL Non-Hodgkin's lymphoma
  • lymphoma aggressive lymphoma, indolent lymphoma
  • histologically e.g. follicular lymphoma, mantle cell lymphoma
  • follicular lymphoma mantle cell lymphoma
  • B lymphocyte T lymphocyte
  • leukemias and related malignancies include acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
  • Other hematological malignancies include the plasma cell dyscrasias including multiple myeloma, and the myelodysplastic syndromes.
  • Leukemias have lower patient numbers. However, there remains substantial unmet medical need, for example for the treatment of acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL), as illustrated by poor 5-year survival rates.
  • AML acute myelogenous leukemia
  • CLL chronic lymphocytic leukemia
  • adenosine analogs fludarabine, cladribine, and clofarabine
  • the purine analog, pentostatin (2′-deoxycoformycin), an inhibitor of adenosine deaminase has clinical activity against lymphoid malignancies.
  • Nelarabine is a prodrug of the deoxyguanosine analogue ara-G, which is resistant to catabolism by purine nucleoside phosphorylase and has demonstrated activity against T-cell malignancies.
  • cytarabine cytarabine (ara-C) has been evaluated; it is active in a number of hematologic malignancies and is one of the agents used in the treatment of acute myelogenous leukemia.
  • WO 05/066189 discloses a compound having structure 1:
  • This invention relates to compound 1. It also relates to the diastereomer thereof in which the bis amino acid substituted on the phosphorus atom is an L amino acid, as well as such diastereomer substantially free of D amino acid.
  • one embodiment of the invention is an organic acid salt of compound 1 and/or its tautomers and solvates.
  • Another embodiment of the invention is a composition
  • a composition comprising (a) an organic acid salt of compound 1 and/or its tautomers and solvates and (b) a carbohydrate, whereby storage stability of the salt is enhanced.
  • a disclosure e.g. a patient insert
  • the solution optionally is stored for a period of greater than about 1 hour.
  • Suitable organic acids for preparing the salts of this invention typically are compounds containing at least one carboxyl group, including amino acids (naturally occurring or synthetic) such as glutamic acid and aspartic acid, and C 1-16 alkyl and C 6-16 aryl and C 4-16 heteroaryl carboxylic acids such as acetic, glycolic, lactic, pyruvic, malonic, glutaric, tartaric, citric, fumaric, succinic, malic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic and 2-phenoxybenzoic acids, together with any derivative (excluding esters where no carboxyl remains free) thereof having the same root (e.g., “acetoacetic acid”) which is disclosed in the table “Physical Constants of Organic Compounds” pp 3-12 to 3-523 Merck Index 74 th Ed. 1993. Dicarboxylic organic acids are of particular interest. It is within the scope of this invention to employ more than
  • the molar ratio of organic acid to compound 1 is about 1:1.
  • the ratio may be as great as 1 mole of compound 1 to the number of acid groups in the case of polyorganic acids, e.g., a 2:1 ratio of compound 1 to salt for a dicarboxylic acid salt.
  • the proportion is variable, ranging down to 1:1 or less, depending upon the enrichment of the acid functionality and its degree of substitution with acidic functionalities.
  • Suitable formulations of compound 1, whether for veterinary and for human use, optionally comprise one or more acceptable carriers.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the patient.
  • Formulations optionally will contain excipients such as those set forth in the “Handbook of Pharmaceutical Excipients” (1986).
  • Excipients optionally include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, mannitol or dextrose, buffers (e.g., citrate), alkali metal salts, glidants, bulking agents and other substances conventionally found in tablets, capsules, solutions or other compositions suited or intended for therapeutic use.
  • the formulations will not contain conventional tabletting excipients since they usually are formulated for parenteral use.
  • the formulations ideally will be sterile.
  • parenteral preparations will be substantially isotonic.
  • the pH of the formulations optionally ranges from about 5-10, ordinarily about 6-9, typically about 5-6.
  • Parenteral (sterile aqueous) solutions of the organic acid salts of compound 1 optionally comprise a stabilizing amount of carbohydrate, typically a saccharide (mono, di or polysaccharides), glycoside or sugar alcohol (alditols).
  • carbohydrate typically a saccharide (mono, di or polysaccharides), glycoside or sugar alcohol (alditols).
  • Polysaccharides should be biodegradable upon parenteral injection or infusion and include dextrins and starches, typically 3-10 units.
  • Representative carbohydrates include hexoses, aldoses, aldohexoses, aldotrioses (e.g. glyceraldehyde), aldotetroses (e.g. erythrose), aldopentoses (e.g. arabinose), ketoses, ketohexose (e.g.
  • fructose fructose
  • ketopentoses e.g. ribulose
  • maltose sucrose, lactose, ribose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose and talose.
  • carbohydrates conventionally used in parenteral formulations, e.g., mannitol or dextrose.
  • the optical character of the carbohydrate is not critical, but it is desirable for the configuration to be such that the carbohydrate is biodegradable upon parenteral administration.
  • 5% dextrose by weight of solution; pH about 4.2, unbuffered
  • storage in buffered solutions at pH 2, 7 and 9 under the same conditions lead to substantial degradation of compound 1: About 100%, 18% and 76% by weight, respectively.
  • the stabilizing amount of carbohydrate is variable and will depend upon the expected storage conditions and desired shelf life, buffer choice, pH, amount of compound 1, and other factors that will be appreciated by the artisan. Usually, about from 0.5% to 5% by weight of solution will be used. Typically the optimal amount of carbohydrate will be determined by routine experimentation, but the amount generally will not exceed (along with buffers, sodium chloride and the like) an amount that provides isotonicity to the solution. Hyperisotonic concentrates are acceptable, however, if it is expected to dilute the parenteral composition prior to or during infusion.
  • the parenteral solution optionally is buffered (typically with citrate buffer) at about pH 4 to 6.
  • carbohydrate stabilizes the salts of compound 1 in aqueous solution for storage (including administration time) of at least about 60 hours, up to 1 week, 1 month or 1 year, or any intermediate period, depending upon the factors noted above for the concentration of carbohydrate, e.g., the storage temperature and the like.
  • the therapeutic compositions optionally are administered by parenteral routes (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) since these are the most convenient for treatment of malignancies.
  • parenteral routes including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural.
  • Intravenous infusions are generally the administration method of choice.
  • the formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules, vials or flexible infusion bags.
  • the containers optionally will be glass or rigid plastic, but typically will be semirigid or flexible containers fabricated from polyolefins (polyethylene) or plasticized polyvinylchloride.
  • the container is typically single chambered.
  • These containers have at least one integral sterile port to facilitate the sterile entry into the container of a device for accessing the contents (usually syringes or an intravenous set spike).
  • the port provides sterile access for solubilizing solution (if required) and egress of parenteral solutions.
  • An overpouch (usually polyolefin) is optionally provided for the container.
  • the formulation is present in the container as a solution or in dry form. If stored in a substantially anhydrous form, e.g., lyophilized, the formulation will require only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Solutions include tonicity establishing agents such as sodium chloride or a sugar such as mannitol or dextrose. An unexpected advantage of carbohydrate or sugar is an increase in stability of compound 1 salt in stored aqueous solutions.
  • the containers are filled with sterile solution or are filled and then sterilized, e.g., by heat or chemical agents, in accord with known processes. In general, a sterile solution of the formulation is sterile-filled into a flexible container and thereafter optionally lyophilized. Suitable technology for producing the container products of this invention is found in Avis et al., Pharmaceutical Dosage Forms: Parenteral Medications vols. 1 and 3 (1984).
  • the parenteral containers will contain a daily dose or unit daily sub-dose of compound 1 as described below, or an appropriate fraction thereof.
  • any neoplasm including not only hematologic malignancies but also solid tumors of all kinds, e.g., head and neck, lung, kidney, liver, bone, brain and the like, particularly uterine and cervical cancer and dysplasia, melanoma, and cancers of the breast, colon, prostate, lung (small cell and non-small cell) and pancreas.
  • the formulations of this invention are administered either as monotherapy or in combination with other agents for the treatment of hematological malignancies.
  • the formulation of this invention optionally is administered to the patient at substantially the same time as other antineoplastic agent(s), or the agent(s) is combined with the formulation of this invention and then administered simultaneously to the patient.
  • Typical antineoplastic agents useful with compound 1 include any of the therapeutics currently employed in the treatment of malignancies, including those used for hematologic malignancies that are mentioned in the background above.
  • companion agents are administered (a) at substantially the same time but by different administration routes, (b) are combined with the formulation of this invention and administered concurrently, or (c) are administered during alternative periods (for instance during a resting period from treatment with compound 1).
  • the formulation of this invention is therapeutically combined with another antineoplastic agent selected from a distinct class, e.g., a monoclonal antibody.
  • Treatment of NHL typically includes cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab. If used in combination, Compound 1 is administered in a course of therapy together with, or as a replacement of, one or more of the foregoing agents. Compound 1 may also be administered in combination with rituximab. For the therapy of CLL, administer Compound 1 either as monotherapy or in combination with other agents, such as cyclophosphamide and/or rituximab.
  • therapeutic agents suitable for use with compound 1 include etoposide, melphalan, nitrosurea, busulfan, platinum complexes, nonclassic alkylators such as procarbazine, antimetabolites such as folate, purines, adenosine analogues, pyrimidine analogues, vinca alkyloides, and the like.
  • a human efficacious dose for compound 1 (corrected for surface area by the factor of 0.54) of between 0.54 mg/kg IV and 1.62 mg/kg IV or greater, administered as a single dose with repeat dosing at interims of approximately 1 to 14 days, generally weekly or every 2 weeks, typically weekly for 2 doses, depending upon the condition of the patient and tolerance to the infusion, among other factors. Since considerable variation should be expected in suitable doses because of the unique nature of individual cancers, the condition of the patient, patient tolerance and other matters known to the ordinary oncologist, the range of effective doses will be larger than the core experimental model.
  • a dosage range of about from 0.5 to 5.4 mg/kg/day is expected to be suitable.
  • a single dose is suitable, but multiple cycles of dosing are anticipated to be typical, with a resting period of about 10-30, usually 23, days between cycles, again depending upon the condition of the patient and tolerance to the therapeutic as will be apparent to the ordinary artisan.
  • the neutral prodrug (2.60 g) was dissolved in a solution of succinic acid (583 mg) in ethanol (15 mL). Following the addition of 50% v/v n-heptane/ethanol (20 mL), the desired salt was isolated by filtration (2.26 g; M.P. 130° C.).
  • Table 1 shows anti-proliferation EC 50 of compound 1 and its metabolites, cpr-PMEDAP (9-(2-phosphonylmethoxyethyl)-N 6 -cyclopropyl-2,6-diaminopurine), PMEG (9-(2-phosphonylmethoxyethyl)guanine), and PMEDAP (9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine).
  • a variety of compounds that are used for treatment of hematologic malignancies were also tested, including a DNA polymerase inhibitor (ara-C), DNA polymerase/ribonucleotide reductase inhibitors (cladribine, clofarabine, fludarabine, gemcitabine), an adenosine deaminase inhibitor (deoxycoformycin), a DNA methylation inhibitor (decitabine), a DNA alkylator (doxorubicin), and a mitosis inhibitor (vincristine).
  • ara-C DNA polymerase inhibitor
  • cladribine DNA polymerase/ribonucleotide reductase inhibitors
  • cladribine clofarabine, fludarabine, gemcitabine
  • an adenosine deaminase inhibitor deoxycoformycin
  • decitabine DNA methylation inhibitor
  • doxorubicin doxorubicin
  • a mitosis inhibitor vincristine
  • doxorubicin and vincristine are nucleoside analogs; ara-C, gemcitabine, and decitabine are cytosine analogs and the rest are adenosine analogs.
  • cpr-PMEDAP and PMEG can be considered adenosine and guanosine analogs, respectively.
  • T-cell mitogen phytohaemagglutinin (PHA) or a B-cell mitogen pokeweed mitogen (PWM) two T-lymphoid cell lines derived from patients with acute lymphocytic leukemia (CEM and Molt-4), two myeloid cell lines derived from patients with acute myelogenous leukemia (KG-1 and HL-60), two B-lymphoid cell lines derived from Burkitt's lymphoma (Daudi and Raji), a B-lymphoid cell line from non-Hodgkin's lymphoma (RL), a T-lymphoid cell line from cutaneous T-lymphoma (PM-1), and a monocytic cell line from histiocytic lymphoma (U937).
  • PHA phytohaemagglutinin
  • PWM B-cell mitogen pokeweed mitogen
  • Compound 1 exhibited anti-proliferative activity in a variety of lymphoblasts and leukemia/lymphoma cell lines. Its EC 50 range was between 27 and 1043 nM, similar to those of clofarabine (25-418 nM) and ara-C (23-1820 nM), two nucleoside analogs commonly used for the treatment of hematologic malignancies. Among other nucleosides, gemcitabine was the most potent (3.4-18 nM) and deoxycoformycin was the least potent (>200,000 nM). Among all compounds, vincristine (0.6-5.3 nM) exhibited the highest potency. There was no significant difference in activity of compound 1 in human and canine cells.
  • compound 1 may be effective in both T- and B-cell lymphomas.
  • cpr-PMEDAP which is the hydrolyzed product of compound 1
  • compound 1 was significantly less potent than compound 1, suggesting that the phosphoramidate prodrug enhanced entry of the drug into cells, and that the prodrug moiety was cleaved inside cells.
  • PMEG the deaminated product of cpr-PMEDAP was significantly more potent than the dealkylated product PMEDAP, consistent with the hypothesis that the active molecule for anti-proliferative activity of compound 1 is PMEGpp.
  • the PHA-lymphoblasts were generated by incubating peripheral blood mononuclear cells (PBMC) with the T-cell mitogen PHA, (1 ⁇ g/mL) for 3 days followed by incubation with 10 U/mL interleukin-2 for 4 more days.
  • the PWM-lymphoblasts were generated by incubating B-cells (purified from PBMC using CD19-conjugated magnetic beads) with PWM (20 ⁇ g/mL) for 7 days.
  • Lymphoblasts (150,000 cells per microtiter well) and leukemia/lymphoma cell lines (30,000 cells per well) were incubated with 5-fold serial dilutions of compounds for 3 days.
  • BrdU assay was performed as follows: Lymphoblasts were incubated with 5-fold serial dilutions of compounds in microtiter plates (150,000 cells per well) for 3 days. On Day 3, cells were labeled with 10 ⁇ M BrdU for 3 hrs and the amount of BrdU incorporated into cellular DNA was quantified by Enzyme-Linked Immunosorbent Assay (ELISA).
  • ELISA Enzyme-Linked Immunosorbent Assay
  • XTT reagent sodium 3,3′-[1[(phenylamino) carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate
  • PMS phenazine methosulfate
  • color change mitochondria dehydrogenase reduces yellow-colored XTT to orange-colored formazan salt
  • the experimental data were used to generate sigmoidal dose-response curves and 50% effective concentration (EC 50 ) values were calculated using GraphPad Prism software version 4.00 for Windows (GraphPad Software, San Diego Calif. USA). Assays were repeated 2-20 times, until the standard error of the mean (SEM) became smaller than 50% of the mean value.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/298,987 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies Abandoned US20090258840A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/298,987 US20090258840A1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80098306P 2006-05-16 2006-05-16
US83180506P 2006-07-18 2006-07-18
US12/298,987 US20090258840A1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies
PCT/US2007/011726 WO2007136650A2 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies

Publications (1)

Publication Number Publication Date
US20090258840A1 true US20090258840A1 (en) 2009-10-15

Family

ID=38578698

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/298,987 Abandoned US20090258840A1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies
US11/803,822 Abandoned US20080039427A1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies
US13/070,179 Active US8435969B2 (en) 2006-05-16 2011-03-23 Method and compositions for treating hematological malignancies

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/803,822 Abandoned US20080039427A1 (en) 2006-05-16 2007-05-16 Method and compositions for treating hematological malignancies
US13/070,179 Active US8435969B2 (en) 2006-05-16 2011-03-23 Method and compositions for treating hematological malignancies

Country Status (20)

Country Link
US (3) US20090258840A1 (de)
EP (1) EP2020996B1 (de)
JP (2) JP5544165B2 (de)
KR (1) KR101424832B1 (de)
CN (1) CN101442994B (de)
AT (1) ATE534377T1 (de)
AU (1) AU2007254309B2 (de)
BR (1) BRPI0711646C1 (de)
CA (1) CA2652048C (de)
CY (1) CY1112377T1 (de)
DK (1) DK2020996T3 (de)
EA (1) EA016995B1 (de)
ES (1) ES2377467T3 (de)
HK (1) HK1127913A1 (de)
MX (1) MX2008014665A (de)
NZ (1) NZ572368A (de)
PL (1) PL2020996T3 (de)
PT (1) PT2020996E (de)
SI (1) SI2020996T1 (de)
WO (1) WO2007136650A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172192A1 (en) * 2006-05-16 2011-07-14 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007128721A1 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphe
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
WO2019237957A1 (zh) * 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229225A1 (en) * 2002-05-13 2003-12-11 Reddy K. Raja Novel phosphonic acid based prodrugs of PMEA and its analogues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
PL213214B1 (pl) 2000-07-21 2013-01-31 Gilead Sciences Diastereoizomerycznie wzbogacone proleki fosfonianowych analogów nukleotydowych oraz kompozycje zawierajace takie zwiazki
ES2290281T5 (es) * 2001-02-12 2017-09-11 Wyeth Llc Sal de succinato de O-desmetil-venlafaxina
ATE320256T1 (de) * 2001-11-29 2006-04-15 Pfizer Prod Inc Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
WO2003050108A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
EP1658277B1 (de) * 2003-08-18 2012-04-04 H. Lundbeck A/S Succinat- und malonatsalz von trans-4-(1r,3s)-6-chlor-3-phenylindan-1-yl)-1,2,2-trimethylpiperazin und die verwendung als medikament
EP2204374B1 (de) * 2003-12-30 2012-06-13 Gilead Sciences, Inc. Nucleosidphosphonate und deren Analaga zur Behandlung von HPV-Infektionen
ES2334149T3 (es) 2004-01-21 2010-03-05 Gilead Sciences, Inc. Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria.
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
BRPI0619962A2 (pt) * 2005-12-16 2011-10-25 Wyeth Corp composições liofilizadas de um composto triazolopirimidina
AU2007254309B2 (en) * 2006-05-16 2012-05-03 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229225A1 (en) * 2002-05-13 2003-12-11 Reddy K. Raja Novel phosphonic acid based prodrugs of PMEA and its analogues

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172192A1 (en) * 2006-05-16 2011-07-14 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
US8435969B2 (en) * 2006-05-16 2013-05-07 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies

Also Published As

Publication number Publication date
PL2020996T3 (pl) 2012-04-30
CN101442994A (zh) 2009-05-27
US8435969B2 (en) 2013-05-07
JP2013100324A (ja) 2013-05-23
MX2008014665A (es) 2008-11-28
BRPI0711646C1 (pt) 2021-05-25
EP2020996A2 (de) 2009-02-11
CY1112377T1 (el) 2015-12-09
EP2020996B1 (de) 2011-11-23
ATE534377T1 (de) 2011-12-15
JP5544165B2 (ja) 2014-07-09
KR101424832B1 (ko) 2014-08-06
JP2009537539A (ja) 2009-10-29
KR20090015122A (ko) 2009-02-11
BRPI0711646B8 (pt) 2021-04-06
BRPI0711646A2 (pt) 2011-11-29
EA200802333A1 (ru) 2009-04-28
NZ572368A (en) 2011-04-29
CN101442994B (zh) 2013-03-06
WO2007136650A3 (en) 2008-01-24
AU2007254309A1 (en) 2007-11-29
CA2652048A1 (en) 2007-11-29
AU2007254309B2 (en) 2012-05-03
PT2020996E (pt) 2012-02-20
SI2020996T1 (sl) 2012-03-30
BRPI0711646B1 (pt) 2020-12-01
CA2652048C (en) 2012-12-11
US20110172192A1 (en) 2011-07-14
ES2377467T3 (es) 2012-03-27
EA016995B1 (ru) 2012-09-28
HK1127913A1 (en) 2009-10-09
WO2007136650A2 (en) 2007-11-29
DK2020996T3 (da) 2012-02-27
US20080039427A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
US8435969B2 (en) Method and compositions for treating hematological malignancies
KR100568035B1 (ko) Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드
EP1358198B1 (de) Neue acyclische nukleosidphosphonatderivate, deren salze und verfahren zu deren herstellung
EP2891658B1 (de) Tenofovir-prodrug und pharmazeutische verwendungen davon
US7795238B2 (en) β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
AU2012290089B2 (en) Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
JP2006182779A (ja) ヌクレオチドアナログ
MXPA06013559A (es) Tratamiento de linfoma de celula t usando 10-propargil-10-deazaaminopterina.
AU774720B2 (en) Nucleosides with anti-hepatitis B virus activity
KR19990022752A (ko) 포스포네이트 뉴클레오티드 유도체
EP1334108B1 (de) Arylphosphatderivate von d4t
US20100136029A1 (en) Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies
AU2007216721B2 (en) Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B

Legal Events

Date Code Title Description
AS Assignment

Owner name: GILEAD SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAI, ZHENHONG R.;JABRI, SALMAN Y.;JIN, HAOLUN;AND OTHERS;REEL/FRAME:022241/0892;SIGNING DATES FROM 20090123 TO 20090204

AS Assignment

Owner name: GILEAD SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHONG, LEE S.;LEE, WILLIAM A.;RAY, ADRIAN S;AND OTHERS;REEL/FRAME:022589/0400;SIGNING DATES FROM 20090403 TO 20090410

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION